COMP <GO>
KRYS vs UNH // REVENUE GROWTH (YOY)
Krystal Biotech Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: KRYS 7
— UNH 6
▲ REVENUE GROWTH (YOY) LEADER: KRYS
LAST: $295.90 (-10.95%) • MKT CAP: $8.76B
revenue-growth
33.90%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRYS VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRYS | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 12.38% | +4.12 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.4x | 15.3x | +38.13 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | 6.25% | -4.28 | UNH | /fcf-yield <GO> |
| Operating Margin | 41.50% | 5.32% | +36.18 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 52.60% | 3.53% | +49.07 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 33.90% | 3.33% | +30.57 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.09 | +22.91 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | KRYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.8 | 55.1 | -20.30 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.33 | +0.58 | KRYS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.4x | 17.7x | +21.66 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.76B | $359.43B | -$350.67B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRYS REV | UNH REV | KRYS GROSS % | UNH GROSS % | KRYS FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $447.57B | — | 88.7% | $188.9M | $16.07B |
| FY 2024 | $290.5M | $400.28B | — | 88.3% | $119.2M | $20.70B |
| FY 2023 | $50.7M | $371.62B | — | 89.6% | -$91.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRYS // BETA 0.91
UNH // BETA 0.33